News
January 2025
Loxigen made a notable appearance at the Biotech Showcase & RESI, JPM 2025 at San Francisco, CA, engaging with key industry leaders and exploring new avenues for collaboration.
October 2024
We’re growing. You can find us at our new location at 280 Calhoun St. Charleston, SC 29425
September 2024
Dr. HM Lee joined LoxiGen as a Director of research to empower our efforts to optimize the current lead towards an IND application.
August 2024
LoxiGen announced that it successfully completed the Phase I of the Fast-track STTR grant -nearly $2.5M in funding- from the National Institutes of Health (NIH) and moved to the Phase II.
July 2024
The paper describing the lead compound LXG6403 is published in Cell Chemical Biology.
Link: https://www.cell.com/cell-chemical-biology/fulltext/S2451-9456(24)00273-3
April 2024
LoxiGen, Inc. is selected for the highly prestigious Life Science Incubator Program of Innosphere Ventures.
June 2023
The National Cancer Institute has awarded LoxiGen, Inc., a three-year Fast-track Small Business Technology Transfer (STTR) grant to develop LOX inhibitors for drug-resistant TNBC in collaboration with scientists at MUSC and USC.